数据出境的新合规要求

2023年2月24日,国家互联网信息办公室公布《个人信息出境标准合同办法》(以下简称《办法》)并于 2023 年 6 月 1 日生效。《办法》明确了个人信息出境标准合同(以下简称"标准合同")的订立、备案等要求,为《个人信息保护法》视域下的个人信息跨境方式之一的"标准合同"提供了落地蓝本与中国方案。新合规要求将对跨行业的跨国公司产生重大影响。


医疗保健、制药和生命科学行业与健康数据和医疗数据等敏感的个人数据有着密切的联系。 后疫情时代,互联网医疗、医疗器械数字化、医药制造等方兴未艾。 鉴于健康和医疗数据的高度敏感性,跨国公司在收集和处理医疗和健康数据方面的合规性面临越来越大的挑战,特别是如何管理与中国相关的跨境数据传输。 《数据跨境传输标准合同条款办法》(2 月 24 日发布,6 月 1 日生效)将对跨国公司产生重大影响,尤其是在信息数据、能源、制药、医疗器械和生命科学领域。


中国美国商会法律工作组和医疗工作组将共同举办此活动,我们邀请Reedsmith律所的专家分享专业见解,主要讨论中国SCC与跨国公司通常采用的国际SCC比较及协同效应,以及探讨采取哪些行动来确保企业数据出境的合规性和风险管理。我们还将提供问答环节,由专业法律人士为企业解惑答疑。


活动详情:

  • 活动形式:线上+线下
  • 线下地点:北京市朝阳区建国门外大街1号国贸写字楼1座1101室,礼德律师事务所
  • 时间和日期:3 月 21 日,下午 3:00 - 4:30
  • 联系人:Ada Yang,ayang@amchamchina.org;Edward Wang, xwang@amchamchina.org


注意:

  • 活动需要线上注册,我们不接受现场注册。 请提前购票。 注册将于 3 月 20 日下午 5:00 截止。
  • 活动开始前48小时票不可退还。
  • 请务必使用您公司的电子邮件地址进行注册。


Cyberspace Administration of China issued the Measures on Standard Contracts for Personal Information Export ("Standard Contracts Measures") on February 24, 2023, which will be effective on June 1, 2023. So far, the legal basis for the three approaches for personal information processors to provide personal information outside the People's Republic of China stipulated in Article 38 of the Personal Information Protection Law has been completed. Compared with "security assessment" and "personal information protection certification", concluding a "standard contract" is undoubtedly the most direct and convenient way among the three approaches. It will affect a lot of Foreign companies in China.


Healthcare, pharma and life sciences industries have close connections with sensitive personal data such as health data and medical data. In the post-COVID era, Internet healthcare and digitalization of medical devices and pharma manufacturing have been booming. Given the high sensitivity of health and medical data, MNCs are facing increasingly significant challenges in achieving compliance in collecting and processing medical and health data, particularly how to manage China-related cross-border data transfers. The Measures on the Standard Contract Clauses for Cross-Border Data Transfer (issued on 24 February and effective on 1 June) will have significant implications for MNCs especially in the healthcare, pharma, medical devices and life sciences sectors.


The legal committee and Healthcare committee of AmCham China will jointly hold this event and invite specialist from ReedSmith to share their insights. We will discuss the comparison between China's SCCs and international SCCs usually adopted by MNCs, and explore what actions can be taken to ensure compliance and risk management. There will be Q&A session at the end. The member companies can share their challenges and our guest speaker will help to provide the suggestions.


Event Details:

  • Event format: Hybrid
  • Offline venue: 1101 China World Office 1, 1 Jianguomenwai Avenue, Beijing
  • Time & Date: March 21, 3:00pm - 4:30pm
  • Contact: Ada Yang, ayang@amchamchina.org; Edward Wang, xwang@amchamchina.org


Notes:

  • Registration is required and due to limited capacity, we cannot accept registrations at the door. Please purchase your tickets in advance. Registration will close at 5:00 PM, March 20.
  • Tickets are non-refundable within 48 hours before the start of event.
  • Please make sure to register with your company email address.




Agenda

3:00 PM - 3:05 PM
Opening Remarks
3:05 PM - 4:00 PM
Presentation
4:00 PM - 4:30 PM
Q&A

Speakers

  • Jery(Shaochun) LI (Leader of IBM GCG Healthcare & Life Sciences at IBM GCG Healthcare & Life Sciences)

    Jery(Shaochun) LI

    Leader of IBM GCG Healthcare & Life Sciences at IBM GCG Healthcare & Life Sciences

    Jery (Shaochun) Li is the Leader of IBM GCG Healthcare & Life Sciences, formal GM of IBM GCG Watson Health. He is consistently focusing on driving IBM Consulting , IBM Technology and Ecosystem solutions to support the digital reinvention of the entire value chain of IBM strategic customers in the Healthcare and Life Sciences industries, to provide healthcare and life sciences professionals with the insights needed to make critical medical, clinical, operational and financial decisions, enabling companies and organizations to use cutting-edge technology to achieve credible digital smart healthcare transformation. IBM brings together researchers, data scientists, clinicians, government, business and thought leaders into collaboration bringing data, technology and expertise together to transform health into Smarter Health Ecosystem.

    view more
  • Barbara Li (Partner at Reedsmith LLP)

    Barbara Li

    Partner at Reedsmith LLP

    Barbara 是国际律师事务所 ReedSmith 全球公司业务组的公司/数据合伙人。 Barbara 拥有超过 25 年的经验,包括在国际和中国领先律师事务所北京和伦敦办事处担任合伙人、在爱立信(中国)担任高级内部职务。
    Barbara 在中国市场被广泛认为是一位杰出的数据/技术和并购律师,被 Legal500、Chambers、Asian Legal Business 和 IFLR 等多个法律名录排名。 她在为跨国公司、金融机构和中国公司就大型复杂数据和网络安全项目提供咨询方面拥有丰富的经验,包括审查和制定数据合规战略和计划、起草数据政策和法律文件、为跨境数据传输提供法律支持,以及管理 数据泄露事件的法律风险,涉及广泛的行业,包括制药、医疗保健、生命科学、汽车、金融、电子商务、能源、基础设施、消费品牌、技术、电信和高端制造。
    Barbara 还经常受客户委托,为跨境并购、合资企业、战略联盟和商业交易提供法律支持。

    view more
  • Edward Wang (Director of AmCham China)

    Edward Wang

    Director of AmCham China

    Director of Healthcare Industry

    view more

Tickets

AmCham China-Member
Standard Price RMB 150
AmCham China-Non-Member
Standard Price RMB 450
From Reedsmith
Standard Price RMB 150